BBA
JBIO

Baker Bros. Advisors’s Jade Biosciences JBIO Stock Holding History

Baker Bros. Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.1M Hold
1,641,137
– – 0.13% 47
2025
Q4 		$25.3M Buy
+1,641,137
New +$19.3M 0.15% 46
2024
Q4 		– Sell
-17,970
Closed -$1.31M – 97
2024
Q3 		$1.31M Hold
17,970
– – 0.01% 84
2024
Q2 		$1.04M Sell
17,970
-30,045
-63% -$19.9M 0.01% 86
2024
Q1 		$49.7M Hold
48,015
– – 0.62% 25
2023
Q4 		$38M Sell
48,015
-8,084
-14% -$4.12M 0.43% 28
2023
Q3 		$26.6M Hold
56,099
– – 0.15% 31
2023
Q2 		$33.7M Hold
56,099
– – 0.19% 32
2023
Q1 		$39.6M Sell
56,099
-383
-0.7% -$318K 0.22% 25
2022
Q4 		$57.9M Sell
56,482
-77
-0.1% -$55.9K 0.35% 23
2022
Q3 		$32.8M Sell
56,559
-2,584
-4% -$1.73M 0.21% 34
2022
Q2 		$32.4M Hold
59,143
– – 0.18% 34
2022
Q1 		$37.9M Buy
59,143
+6,806
+13% +$2.64M 0.22% 38
2021
Q4 		$21.6M Buy
52,337
+5,132
+11% +$2.6M 0.11% 57
2021
Q3 		$34.7M Buy
47,205
+6,389
+16% +$3.58M 0.15% 48
2021
Q2 		$32.6M Buy
+40,816
New +$32.6M 0.14% 52

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Baker Bros. Advisors's JBIO Position: Q1 2026 in Review

Baker Bros. Advisors held its Jade Biosciences (JBIO) position steady in Q1 2026 at 1,641,137 shares worth $23.1M. The position accounts for 0.13% of the portfolio, ranked #47.

Baker Bros. Advisors first reported a position in JBIO in Q2 2021 and has held it in 16 quarters since. The position peaked at $57.9M in Q4 2022. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Baker Bros. Advisors held 1,641,137 shares of Jade Biosciences worth $23.1M as of Q1 2026.
  • Baker Bros. Advisors left its Jade Biosciences share count unchanged in Q1 2026.
  • Jade Biosciences made up 0.13% of Baker Bros. Advisors's portfolio in Q1 2026, its #47 holding.
  • Baker Bros. Advisors first reported a position in Jade Biosciences in Q2 2021 and has held it in 16 quarters since.
  • Baker Bros. Advisors's Jade Biosciences position peaked at $57.9M in Q4 2022.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.